In the article cited above, the content in Table 9.2 regarding clinical considerations for the class of medications glucagon-like peptide 1 receptor agonists (GLP1-RAs) has been amended to reflect counseling patients about potential for ileus for all medications in this class.

The original content for clinical considerations for GLP1-RAs appeared as follows:

“Counsel patients about potential for ileus (semaglutide SQ)”

The revised content for clinical considerations for GLP1-RAs now reads:

“Counsel patients about potential for ileus”

The online version of Section 9 (https://doi.org/10.2337/dc24-S009) has been updated with the revised text.

*

A complete list of members of the American Diabetes Association Professional Practice Committee can be found at https://doi.org/10.2337/dc24-SINT.

This content is only available via PDF.
Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at https://www.diabetesjournals.org/journals/pages/license.